Moderna Aktie
| 23,67USD | -0,06USD | -0,25% |
WKN DE: A2N9D9 / ISIN: US60770K1079
Personal
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 1 300 | 2 700 | 3 900 | 5 600 | 5 800 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,62 | 6,82 | 4,90 | 1,22 | 0,56 |
Bilanz (in Mio. USD) - Aktiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 6 298 | 16 071 | 13 431 | 10 325 | 8 099 |
| Summe Anlagevermögen | 1 039 | 8 798 | 12 656 | 8 101 | 6 043 |
| Summe Aktiva | 7 337 | 24 869 | 26 087 | 18 426 | 14 142 |
Bilanz (in Mio. USD) - Passiva
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 4 775 | 10 724 | 6 964 | 4 572 | 3 241 |
| Summe Eigenkapital | 2 561 | 14 145 | 19 123 | 13 854 | 10 901 |
| Summe Passiva | 7 337 | 24 869 | 26 087 | 18 426 | 14 142 |
Adresse
| 325 Binney Street, 02142 Cambridge | |
| Telefon | +1 (617) 714-6500 |
| Internet | http://www.modernatx.com |
Management
|
Charbel Haber
Senior Vice President-Regulatory Science |
|
David Mark Rubenstein
Independent Director |
|
Elizabeth E. Tallett
Independent Director |
|
Elizabeth G. Nabel
Independent Director |
|
Francois Nader
Independent Director |
|
Jacqueline Miller
Chief Medical Officer |
|
James M. Mock
Chief Financial Officer |
|
Jerh Collins
Chief Technical Operations & Quality Officer |
|
Lavina A. Talukdar
Senior Vice President & Head-Investor Relations |
|
Noubar B. Afeyan
Chairman |
|
Paul L. Sagan
Independent Director |
|
Rose Loughlin
Executive Vice President-Research |
|
Sandra J. Horning
Independent Director |
|
Shah Abbas Hussain
Independent Director |
|
Shannon Thyme Klinger
Secretary & Chief Legal Officer |
|
Stephen Hoge
President |
|
Stéphane Bancel
Chief Executive Officer & Director |
|
Tracey Franklin
Chief People & Digital Technology Officer |